Publication

Autoantibodies to box A of high mobility group box 1 in systemic lupus erythematosus

Schaper, F., de Leeuw, K., Horst, G., Maas, F., Bootsma, H., Heeringa, P., Limburg, P. C. & Westra, J., Jun-2017, In : Clinical and Experimental Immunology. 188, 3, p. 412-419 8 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Schaper, F., de Leeuw, K., Horst, G., Maas, F., Bootsma, H., Heeringa, P., ... Westra, J. (2017). Autoantibodies to box A of high mobility group box 1 in systemic lupus erythematosus. Clinical and Experimental Immunology, 188(3), 412-419. https://doi.org/10.1111/cei.12951

Author

Schaper, F. ; de Leeuw, K. ; Horst, G. ; Maas, F. ; Bootsma, H. ; Heeringa, P. ; Limburg, P. C. ; Westra, J. / Autoantibodies to box A of high mobility group box 1 in systemic lupus erythematosus. In: Clinical and Experimental Immunology. 2017 ; Vol. 188, No. 3. pp. 412-419.

Harvard

Schaper, F, de Leeuw, K, Horst, G, Maas, F, Bootsma, H, Heeringa, P, Limburg, PC & Westra, J 2017, 'Autoantibodies to box A of high mobility group box 1 in systemic lupus erythematosus', Clinical and Experimental Immunology, vol. 188, no. 3, pp. 412-419. https://doi.org/10.1111/cei.12951

Standard

Autoantibodies to box A of high mobility group box 1 in systemic lupus erythematosus. / Schaper, F.; de Leeuw, K.; Horst, G.; Maas, F.; Bootsma, H.; Heeringa, P.; Limburg, P. C.; Westra, J.

In: Clinical and Experimental Immunology, Vol. 188, No. 3, 06.2017, p. 412-419.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Schaper F, de Leeuw K, Horst G, Maas F, Bootsma H, Heeringa P et al. Autoantibodies to box A of high mobility group box 1 in systemic lupus erythematosus. Clinical and Experimental Immunology. 2017 Jun;188(3):412-419. https://doi.org/10.1111/cei.12951


BibTeX

@article{727d388b84594d72977a894718fddad0,
title = "Autoantibodies to box A of high mobility group box 1 in systemic lupus erythematosus",
abstract = "Autoantibodies to nuclear structures are a hallmark of systemic lupus erythematosus (SLE), including autoantibodies to nuclear protein high mobility group box 1 (HMGB1). HMGB1 consists of three separate domains: box A, box B and an acidic tail. Recombinant box A acts as a competitive antagonist for HMGB1 and might be an interesting treatment option in SLE. However, antibodies to box A might interfere. Therefore, levels of anti-box A were examined in SLE patients in association with disease activity and clinical parameters. Serum anti-box A was measured in 86 SLE patients and 44 age- and sex-matched healthy controls (HC). Serum samples of 28 patients with primary Sjogren's syndrome and 32 patients with rheumatoid arthritis were included as disease controls. Anti-HMGB1 and anti-box B levels were also measured by enzyme-linked immunosorbent assay during quiescent disease [SLE Disease Activity Index (SLEDAI) = 5, n=39). Anti-box A levels in active SLE patients were higher compared to quiescent patients, and were increased significantly compared to HC and disease controls. Anti-box A levels correlated positively with SLEDAI and anti-dsDNA levels and negatively with complement C3 levels. Increased levels of anti-box A antibodies were present in the majority of patients with nephritic (73{\%}) and non-nephritic exacerbations (71{\%}). Antibodies to the box A domain of HMGB1 might be an interesting new biomarker, as these had a high specificity for SLE and were associated with disease activity. Longitudinal studies should be performed to evaluate whether these antibodies perform better in predicting an exacerbation, especially non-nephritic exacerbations.",
keywords = "anti-box A, anti-HMGB1, autoantibodies, HMGB1, SLE, CHROMOSOMAL-PROTEIN 1, DISEASE-ACTIVITY, ANTI-HMGB1 ANTIBODIES, CYTOKINE RELEASE, RECEPTOR 4, ARTHRITIS, MICE, NEPHRITIS, CLASSIFICATION",
author = "F. Schaper and {de Leeuw}, K. and G. Horst and F. Maas and H. Bootsma and P. Heeringa and Limburg, {P. C.} and J. Westra",
note = "{\circledC} 2017 British Society for Immunology.",
year = "2017",
month = "6",
doi = "10.1111/cei.12951",
language = "English",
volume = "188",
pages = "412--419",
journal = "Clinical and Experimental Immunology",
issn = "0009-9104",
publisher = "WILEY",
number = "3",

}

RIS

TY - JOUR

T1 - Autoantibodies to box A of high mobility group box 1 in systemic lupus erythematosus

AU - Schaper, F.

AU - de Leeuw, K.

AU - Horst, G.

AU - Maas, F.

AU - Bootsma, H.

AU - Heeringa, P.

AU - Limburg, P. C.

AU - Westra, J.

N1 - © 2017 British Society for Immunology.

PY - 2017/6

Y1 - 2017/6

N2 - Autoantibodies to nuclear structures are a hallmark of systemic lupus erythematosus (SLE), including autoantibodies to nuclear protein high mobility group box 1 (HMGB1). HMGB1 consists of three separate domains: box A, box B and an acidic tail. Recombinant box A acts as a competitive antagonist for HMGB1 and might be an interesting treatment option in SLE. However, antibodies to box A might interfere. Therefore, levels of anti-box A were examined in SLE patients in association with disease activity and clinical parameters. Serum anti-box A was measured in 86 SLE patients and 44 age- and sex-matched healthy controls (HC). Serum samples of 28 patients with primary Sjogren's syndrome and 32 patients with rheumatoid arthritis were included as disease controls. Anti-HMGB1 and anti-box B levels were also measured by enzyme-linked immunosorbent assay during quiescent disease [SLE Disease Activity Index (SLEDAI) = 5, n=39). Anti-box A levels in active SLE patients were higher compared to quiescent patients, and were increased significantly compared to HC and disease controls. Anti-box A levels correlated positively with SLEDAI and anti-dsDNA levels and negatively with complement C3 levels. Increased levels of anti-box A antibodies were present in the majority of patients with nephritic (73%) and non-nephritic exacerbations (71%). Antibodies to the box A domain of HMGB1 might be an interesting new biomarker, as these had a high specificity for SLE and were associated with disease activity. Longitudinal studies should be performed to evaluate whether these antibodies perform better in predicting an exacerbation, especially non-nephritic exacerbations.

AB - Autoantibodies to nuclear structures are a hallmark of systemic lupus erythematosus (SLE), including autoantibodies to nuclear protein high mobility group box 1 (HMGB1). HMGB1 consists of three separate domains: box A, box B and an acidic tail. Recombinant box A acts as a competitive antagonist for HMGB1 and might be an interesting treatment option in SLE. However, antibodies to box A might interfere. Therefore, levels of anti-box A were examined in SLE patients in association with disease activity and clinical parameters. Serum anti-box A was measured in 86 SLE patients and 44 age- and sex-matched healthy controls (HC). Serum samples of 28 patients with primary Sjogren's syndrome and 32 patients with rheumatoid arthritis were included as disease controls. Anti-HMGB1 and anti-box B levels were also measured by enzyme-linked immunosorbent assay during quiescent disease [SLE Disease Activity Index (SLEDAI) = 5, n=39). Anti-box A levels in active SLE patients were higher compared to quiescent patients, and were increased significantly compared to HC and disease controls. Anti-box A levels correlated positively with SLEDAI and anti-dsDNA levels and negatively with complement C3 levels. Increased levels of anti-box A antibodies were present in the majority of patients with nephritic (73%) and non-nephritic exacerbations (71%). Antibodies to the box A domain of HMGB1 might be an interesting new biomarker, as these had a high specificity for SLE and were associated with disease activity. Longitudinal studies should be performed to evaluate whether these antibodies perform better in predicting an exacerbation, especially non-nephritic exacerbations.

KW - anti-box A

KW - anti-HMGB1

KW - autoantibodies

KW - HMGB1

KW - SLE

KW - CHROMOSOMAL-PROTEIN 1

KW - DISEASE-ACTIVITY

KW - ANTI-HMGB1 ANTIBODIES

KW - CYTOKINE RELEASE

KW - RECEPTOR 4

KW - ARTHRITIS

KW - MICE

KW - NEPHRITIS

KW - CLASSIFICATION

U2 - 10.1111/cei.12951

DO - 10.1111/cei.12951

M3 - Article

VL - 188

SP - 412

EP - 419

JO - Clinical and Experimental Immunology

JF - Clinical and Experimental Immunology

SN - 0009-9104

IS - 3

ER -

ID: 40225620